Please select the option that best describes you:
What are your top takeaways in Myeloma from ASH 2025?
Answer from: Medical Oncologist at Academic Institution
The most clinically impactful MM studies in 2026 would be
MajesTEC-3
RediecTT
LimiTec
Sign In or Register to read more
Answer from: Medical Oncologist at Community Practice
As is probably true for most multiple myeloma-focused investigators, my interest was most piqued by the results of the MajesTEC-3 trial, which demonstrated an 83% 3-year progression-free survival in a population of patients with relapsed or refractory disease resulting from teclistamab and daratumum...
Answer from: Medical Oncologist at Academic Institution
The presentation that will likely have the most immediate and far-reaching consequences would be MajesTEC-3. What was so noteworthy was the incredibly high response, depth of response, and durability. Many colleagues seem eager for the opportunity to use this combination. We will have to see if...
Answer from: at Community Practice
The use of teclistamab + dara (MajesTEC-3 results) compared to DVD or DPD is very promising in first-line relapsed MM patients who are not candidates for CAR-T cells.
COBRA study - use of carfilzomib in high-risk MM seems very promising, though the comparator arm only had velcade use for 32 weeks...
Answer from: Medical Oncologist at Academic Institution
The top abstract undoubtedly was the Phase III MajesTEC-3 trial presented by Dr. Marivi Mateos, which demonstrated significant PFS and OS benefits with teclistamab & daratumumab (tec-dara) versus standard regimens in relapsed myeloma. Once this is approved, decision-making around BCMA CAR-T ve...
Answer from: Medical Oncologist at Academic Institution
LBA-6 (MajesTEC-3): PFS and OS data were, of course, extremely impressive. This combination (teclistamab+daratumumab) will be a true competitor to cilta-cel in the lenalidomide-refractory, PI-exposed, population. This study shows the power of Tec-Dara, and while the change in practice to use of dara...